<DOC>
	<DOCNO>NCT01911234</DOCNO>
	<brief_summary>The safety immunogenicity TNF-Kinoid ( TNF-K ) evaluate phase II clinical study conduct subject Rheumatoid arthritis . Preliminary result clinical efficacy promising . The principal aim present study confirm clinical efficacy TNF-K subject Rheumatoid arthritis treatment methotrexate work anymore . Subjects never treat anti-TNFα monoclonal antibody enrol trial . In addition , immune response safety elicit TNF-K also evaluate .</brief_summary>
	<brief_title>Clinical Efficacy TNF-Kinoid Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Has diagnosis RA accord revise ACR criterion ( Aletaha et al . 2010 ) least 6 month . Has treat tolerate MTX least 3 month prior first administration study product , Has least four swollen joints/66 and/or four tender joints/68 , Has CRP ≥ 10 mg/L screening . Is positive rheumatoid factor ( RF ) anticyclic citrullinated peptide ( CCP ) antibodies screen . Has inflammatory rheumatic disease RA Has treat nonbiological DMARDs/systemic immunosuppressive Has treat leflunomide within 12 week prior first administration study product . Has receive intraarticular , intramuscular ( IM ) , intravenous ( IV ) corticosteroid Has receive infliximab , etanercept , adalimumab , certolizumab , golimumab ; another TNFα antagonist ; rituximab prior study . Has treat biological DMARDs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>